abiraterone acetate • Eligard (leuprolide acetate) • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Viadur (leuprorelin implant) • Yonsa (abiraterone acetate)

Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial (clinicaltrials.gov)

P3, N=1524, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting | Initiation date: Oct 2025 --> Mar 2026

3 days ago

Enrollment open • Trial initiation date

FOLH1 positive

Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

Preclinical Theranostic Study of 68Ga/177Lu/225Ac-Labeled Bicyclic Peptides Targeting Nectin‑4 in Lung Cancer. (PubMed, ACS Omega)

[177Lu]-Lu-6 showed superior tumor retention (13% uptake) and internalization (3.5%) compared to [177Lu]-Lu-FAP-2286/N188, with sustained tumor growth suppression in xenograft models. PET/SPECT imaging revealed high tumor-to-background ratios and favorable pharmacokinetics, highlighting the potential of these agents for clinical application.

3 days ago

Preclinical • Journal

NECTIN4 (Nectin Cell Adhesion Molecule 4)

lutetium Lu 177 rofapitide tetraxetan (AAA614)

Imaging of Adrenal and Extra-Adrenal Paraganglioma. (PubMed, Semin Ultrasound CT MR)

Contemporary consensus places somatostatin‑receptor analogues (SSAs) such as 68Ga-DOTATATE and 64Cu-DOTATATE at the center of head‑and‑neck paraganglioma (HNPGL), SDHx‑mutated disease, sporadic or hereditary HNPGLs and metastatic PPGLs, while 18F‑FDOPA is increasingly favored for adrenal pheochromocytoma (PCC); and 18F‑FDG complements both by detecting aggressive biology. MIBG now is only considered for inoperable or metastatic PPGLs under consideration for 131I‑MIBG therapy.

3 days ago

Review • Journal

SSTR (Somatostatin Receptor)

Azedra (iobenguane I 131)

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function (clinicaltrials.gov)

P2, N=23, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jun 2026 --> Dec 2026

4 days ago

Enrollment closed • Trial completion date • Trial primary completion date

Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors (clinicaltrials.gov)

P1, N=29, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jun 2026 --> Dec 2026

4 days ago

Trial completion date • Trial primary completion date

peposertib (M3814) • Lutathera (lutetium Lu 177 dotatate)

Natural Flavonoids Genistein and Baicalein as Well-Tolerated Radiosensitizers to Enhance the Efficacy of 177Lu-PSMA617 in Prostate Cancer: In Vitro and In Vivo Studies. (PubMed, Research (Wash D C))

Their natural origin and established safety profile underscore their translational potential. Thus, genistein and baicalein represent promising novel adjuvants for prostate cancer radioligand therapy.

6 days ago

Preclinical • Journal

CASP3 (Caspase 3)

Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

RECIP: Prognostic Value of 177Lutetium-PSMA Single Photon Emission Tomography and Timing of Response (clinicaltrials.gov)

P=N/A, N=280, Not yet recruiting, Central Hospital, Nancy, France

6 days ago

New trial

lutetium zadavotide guraxetan (PNT2002)

Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T therapy: dosimetry results. (PubMed, Eur J Nucl Med Mol Imaging)

In this pilot cohort, concomitant ARSi therapy did not significantly enhance tumor absorbed doses in patients receiving [177Lu]Lu-PSMA-617 or [177Lu]Lu-PSMA-I&T RLT. Further prospective studies with larger patient numbers are needed to evaluate the impact of concomitant ARSi treatment on the absorbed doses in mCRPC tumor lesions.

7 days ago

Journal

FOLH1 (Folate hydrolase 1) • ARSI (Arylsulfatase Family Member I)

FOLH1 expression

enzalutamide • abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

Lanmodulin-Engineered Outer Membrane Vesicles for Synergistic Targeted Radio-Immunotherapy. (PubMed, ACS Nano)

In a head-to-head comparison with clinically approved 177Lu-PSMA-617 (Pluvicto), PSMA-targeted TRT@LnOMVs achieved a 90% survival rate in a prostate cancer model, far surpassing the 25% survival rate of Pluvicto...This occurred through reprogramming immunosuppressive myeloid compartments (including neutrophil subsets and macrophages), expanding cytotoxic CD8+ T and NK cell infiltration, and activating innate immunity to trigger robust antitumor responses. Collectively, TRT@LnOMVs represent a versatile class of biohybrid therapeutics, offering a robust paradigm for next-generation radio-immunotherapy.

9 days ago

Journal

CD8 (cluster of differentiation 8)

Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

Feasibility of treating neuroendocrine prostate cancer with anti-SSTR radioligands: A systematic review of imaging and treatment studies. (PubMed, Semin Nucl Med)

SSTR expression in NEPC is heterogeneous. SSTR imaging can support phenotyping and selection for SSTR directed therapy in selected patients, including PSMA low disease, but prospective validation with standardized reporting is needed.

9 days ago

Review • Journal

SSTR (Somatostatin Receptor)

Lutathera (lutetium Lu 177 dotatate)

Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere (clinicaltrials.gov)

P3, N=108, Active, not recruiting, Chengdu New Radiomedicine Technology Co. LTD. | Recruiting --> Active, not recruiting

9 days ago

Enrollment closed